NCT02782949: Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia
- State
- Under way
- Phase
- Phase 2
- People
- 50 taking part
- Started
- 4 Apr 2017
- Primary completion
- 6 Oct 2022
- Arms
- Arm I (curcumin)
- Results
- Posted on the registry
- 26 May 2016: Trial registered
- 4 Apr 2017: Trial started
- 5 Mar 2024: Trial results posted
Posted results
The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.
Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa
Primary outcome · Median, pg/mL · Baseline up to 6 months
| Group | Analysed | Value |
|---|---|---|
| Arm I (Curcumin) Antrum: IL-1beta Difference | 22 | 0.0 (Full Range -4.2 to 10.9) |
| Arm II (Placebo) Antrum: IL-1beta Difference | 25 | -0.1 (Full Range -5.5 to 4.1) |
| Arm I (Curcumin) Body: IL-1beta Difference | 22 | 0.0 (Full Range -5.2 to 4.2) |
| Arm II (Placebo) Body: IL-1beta Difference | 25 | 0.1 (Full Range -0.8 to 8.6) |
- p = 0.3990, Wilcoxon Rank-Sum test (superiority test). Posted for: Arm I (Curcumin), Arm II (Placebo)
Change in Histology Gastric Score
Secondary outcome · Median, scores on a scale · Baseline up to 6 months
| Group | Analysed | Value |
|---|---|---|
| Arm I (Curcumin) Correa Score Difference (Puerto Rico data) central review | 22 | 0.0 (Full Range -2.8 to 3.6) |
| Arm II (Placebo) Correa Score Difference (Puerto Rico data) central review | 25 | 0.0 (Full Range -3.6 to 2.6) |
| Arm I (Curcumin) Correa Score Difference (UAB data) | 22 | 0.0 (Full Range -3.6 to 3.6) |
| Arm II (Placebo) Correa Score Difference (UAB data) | 25 | 0.0 (Full Range -3.9 to 3.5) |
Additional Gastric Mucosal Cytokine/Chemokine Levels (TNFalpha, and IP-10)
Secondary outcome · Median, pg/mL · Baseline up to 6 months
| Group | Analysed | Value |
|---|---|---|
| Arm I (Curcumin) Antrum: TNF-alpha Difference | 22 | -0.1 (Full Range -3.8 to 5.7) |
| Arm II (Placebo) Antrum: TNF-alpha Difference | 25 | 0.0 (Full Range -1.8 to 8.7) |
| Arm I (Curcumin) Antrum: IP-10 Difference | 22 | 8.0 (Full Range -135.7 to 285.9) |
| Arm II (Placebo) Antrum: IP-10 Difference | 25 | 14.3 (Full Range -218.3 to 179.2) |
| Arm I (Curcumin) Body: IP-10 Difference | 22 | 1.2 (Full Range -356.5 to 217.0) |
| Arm II (Placebo) Body: IP-10 Difference | 25 | 5.2 (Full Range -132.3 to 157.9) |
| Arm I (Curcumin) Body: TNF-alpha Difference | 22 | 0.0 (Full Range -1.8 to 4.6) |
| Arm II (Placebo) Body: TNF-alpha Difference | 25 | 0.0 (Full Range -8.0 to 12.0) |
| Arm I (Curcumin) Antrum: IL-8 Difference | 22 | -0.3 (Full Range -30.7 to 12.4) |
| Arm II (Placebo) Antrum: IL-8 Difference | 25 | -0.2 (Full Range -55.4 to 385.2) |
| Arm I (Curcumin) Body: IL-8 Difference | 22 | 0.0 (Full Range -1.8 to 4.6) |
| Arm II (Placebo) Body: IL-8 Difference | 25 | 0.0 (Full Range -8.0 to 12.0) |
Gastric Mucosal Deoxyribonucleic Acid (DNA) Damage
Secondary outcome · Number of participants · Baseline up to 6 months
| Group | Analysed | Value |
|---|---|---|
| Arm I (Curcumin) DNA Damage: Baseline, < 1% | 22 | 18 |
| Arm II (Placebo) DNA Damage: Baseline, < 1% | 25 | 19 |
| Arm I (Curcumin) DNA Damage: Baseline, 1-5% | 22 | 2 |
| Arm II (Placebo) DNA Damage: Baseline, 1-5% | 25 | 4 |
| Arm I (Curcumin) DNA Damage: Baseline, >5% | 22 | 2 |
| Arm II (Placebo) DNA Damage: Baseline, >5% | 25 | 1 |
| Arm I (Curcumin) DNA Damage: Baseline, Missing | 22 | 0 |
| Arm II (Placebo) DNA Damage: Baseline, Missing | 25 | 1 |
| Arm I (Curcumin) DNA Damage: Month 6, < 1% | 22 | 19 |
| Arm II (Placebo) DNA Damage: Month 6, < 1% | 25 | 13 |
| Arm I (Curcumin) DNA Damage: Month 6, 1-5% | 22 | 2 |
| Arm II (Placebo) DNA Damage: Month 6, 1-5% | 25 | 10 |
| Arm I (Curcumin) DNA Damage: Month 6, >5% | 22 | 1 |
| Arm II (Placebo) DNA Damage: Month 6, >5% | 25 | 1 |
| Arm I (Curcumin) DNA Damage: Month 6, Missing | 22 | 0 |
| Arm II (Placebo) DNA Damage: Month 6, Missing | 25 | 1 |
- p = 0.74, Fisher Exact (superiority test). Posted for: Arm I (Curcumin), Arm II (Placebo)